GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (TSXV:IPCI) » Definitions » Cyclically Adjusted Revenue per Share

IntelliPharmaCeutics International (TSXV:IPCI) Cyclically Adjusted Revenue per Share : C$1.56 (As of Aug. 2023)


View and export this data going back to 1999. Start your Free Trial

What is IntelliPharmaCeutics International Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

IntelliPharmaCeutics International's adjusted revenue per share for the three months ended in Aug. 2023 was C$0.003. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is C$1.56 for the trailing ten years ended in Aug. 2023.

During the past 12 months, IntelliPharmaCeutics International's average Cyclically Adjusted Revenue Growth Rate was -7.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -3.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of IntelliPharmaCeutics International was 20.70% per year. The lowest was -11.80% per year. And the median was -4.60% per year.

As of today (2024-05-21), IntelliPharmaCeutics International's current stock price is C$0.08. IntelliPharmaCeutics International's Cyclically Adjusted Revenue per Share for the quarter that ended in Aug. 2023 was C$1.56. IntelliPharmaCeutics International's Cyclically Adjusted PS Ratio of today is 0.05.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of IntelliPharmaCeutics International was 26.65. The lowest was 0.03. And the median was 1.81.


IntelliPharmaCeutics International Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for IntelliPharmaCeutics International's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Cyclically Adjusted Revenue per Share Chart

IntelliPharmaCeutics International Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.05 1.85 1.60 - 1.64

IntelliPharmaCeutics International Quarterly Data
Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.68 1.64 1.60 1.58 1.56

Competitive Comparison of IntelliPharmaCeutics International's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, IntelliPharmaCeutics International's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IntelliPharmaCeutics International's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's Cyclically Adjusted PS Ratio falls into.



IntelliPharmaCeutics International Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, IntelliPharmaCeutics International's adjusted Revenue per Share data for the three months ended in Aug. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Aug. 2023 (Change)*Current CPI (Aug. 2023)
=0.003/125.3885*125.3885
=0.003

Current CPI (Aug. 2023) = 125.3885.

IntelliPharmaCeutics International Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201311 0.754 97.182 0.973
201402 2.196 98.051 2.808
201405 0.693 99.394 0.874
201408 0.502 99.315 0.634
201411 0.746 99.078 0.944
201502 0.607 99.078 0.768
201505 0.655 100.263 0.819
201508 0.462 100.579 0.576
201511 0.460 100.421 0.574
201602 0.320 100.421 0.400
201605 0.291 101.765 0.359
201608 0.254 101.686 0.313
201611 0.262 101.607 0.323
201702 0.540 102.476 0.661
201705 0.896 103.108 1.090
201708 0.488 103.108 0.593
201711 0.418 103.740 0.505
201802 0.122 104.688 0.146
201805 0.018 105.399 0.021
201808 0.124 106.031 0.147
201811 0.073 105.478 0.087
201902 0.023 106.268 0.027
201905 0.078 107.927 0.091
201908 0.102 108.085 0.118
201911 0.014 107.769 0.016
202002 0.022 108.559 0.025
202005 0.023 107.532 0.027
202008 0.017 108.243 0.020
202011 0.017 108.796 0.020
202102 0.000 109.745 0.000
202105 0.004 111.404 0.005
202108 0.000 112.668 0.000
202111 0.000 113.932 0.000
202202 0.003 115.986 0.003
202205 0.000 120.016 0.000
202208 0.001 120.569 0.001
202211 0.001 121.675 0.001
202302 0.013 122.070 0.013
202305 0.020 124.045 0.020
202308 0.003 125.389 0.003

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


IntelliPharmaCeutics International  (TSXV:IPCI) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

IntelliPharmaCeutics International's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.08/1.56
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of IntelliPharmaCeutics International was 26.65. The lowest was 0.03. And the median was 1.81.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


IntelliPharmaCeutics International Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


IntelliPharmaCeutics International (TSXV:IPCI) Business Description

Traded in Other Exchanges
Address
30 Worcester Road, Toronto, ON, CAN, M9W 5X2
IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.

IntelliPharmaCeutics International (TSXV:IPCI) Headlines

No Headlines